Q2 FY2026 · ended Jun 30, 2026 · Revenue $1.05M, -65.8% YoY · Filed Aug 12, 2026
Tscan Therapeutics, Inc. (TCRX) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $1.1 million and a net loss of $30.4 million. Free cash flow was -$28.0 million. As of Jun 30, 2026 it held $100.2 million in cash and investments and $90.9 million in total debt.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1783328
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $1.1M | $982,000 | $2.6M | $2.5M | $3.1M |
| Operating income | -$30.5M | -$29.1M | -$23.9M | -$37.1M | -$38.7M |
| Net income | -$30.4M | -$28.7M | -$23.0M | -$35.7M | -$37.0M |
| Diluted EPS | -$0.23 | -$0.22 | -$0.18 | -$0.28 | -$0.28 |
| Operating cash flow | -$27.5M | -$24.3M | -$32.0M | -$32.5M | -$33.3M |
| Free cash flow | -$28.0M | -$24.3M | -$32.2M | -$33.9M | -$34.5M |
| Total assets | $171.5M | $202.0M | $228.8M | $262.2M | $298.6M |
| Total liabilities | $102.4M | $105.1M | $105.7M | $118.2M | $121.8M |
| Stockholders' equity | $69.0M | $96.9M | $123.1M | $144.0M | $176.7M |
| Cash and investments | $100.2M | $128.1M | $152.4M | $184.5M | $218.0M |
| Total debt | $90.9M | $92.5M | $94.1M | $95.6M | $96.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 30, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Listing notice, Officer or director change, Regulation FD disclosure, Other events
|
Sep 2, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Agreement ended
|
Aug 18, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
All 334 Tscan Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.